The role and place of cardioprotection with modern infusion solutions in the perioperative period

Yu.O. Ploschenko, O.M. Klygunenko


Cardiovascular diseases are major health and social problem in the world. Prevention of cardiac complications in extracardial surgical interventions is one of the most urgent problems of modern anesthesiology, surgery and cardiology. Abroad, detailed recommendations are published on optimal diagnostic and therapeutic management in these settings; similar recommendations were issued in Russia. Unfortunately, our country still has no such regulatory documents on the subject. Complications caused by myocardial ischemia most often develop in patients with coronary heart disease that cause long and traumatic surgery. Decompensation of concomitant coronary artery disease with a decrease in contractile function of the left ventricle is most common in elderly and senile age. The incidence of cardiac complications after general operations in the elderly is 9.1 %, mortality in such complications could reach 45.5 %. Cardiac complications significantly increase the length and cost of treatment, creates conditions for the development of multiple organ failure and violation of reparative processes in the zone of surgery. Thus, it is clear that prevention and timely adequate treatment of cardiac complications is an important tactical and strategic task. Unfortunately, possibilities to radically reduce the risk of cardiac complications due to changes in the type of anesthetic provision are sufficiently limited for a number of reasons. Therefore, it is quite obvious that anesthetists are interested in effective perioperative pharmacological myocardial protection — cardioprotection. The concept of cardioprotection includes all the mechanisms and ways to prevent heart damage by preventing or reducing the degree of myocardial cell damage. Cardioprotective therapy is the treatment that through direct effects on cardiomyocytes contributes to its survival in ischemia-hypoxia. Another one very important criterion for the anesthesiologist is the absence of hemodynamic actions, such ideal preparation should improve long-term prognosis of the disease. Today, there are about 2000 molecules with a direct protective effect on the heart. However, only a few drugs with cardioprotective properties are being introduced in real clinical practice. Drugs which contain amino acids L-arginine and L-carnitine can be effectively used as cardioprotective drugs. The main feature of cardioprotective therapy infusion from the modern point of view is the use of solutions with balanced multicomponent composition in a small volume of liquid. The results of researches in this field and changes based on them in official recommendations indicate that the introduction of such approaches in clinical practice in the near future will be important to improve the efficiency and safety of perioperative infusion therapy in patients with cardiovascular diseases.


cardioprotection; peryoperative period; infusion therapy; L-arginine; L-carnitine


Kristensen S.D., Knuuti J., Saraste A., Anker S., Bøt­ker H.E., Hert S.D., Ford I., Gonzalez-Juanatey J.R., Gorenek B., Heyndrickx G.R., Hoeft A., Huber K., Iung B., Kjeldsen K.P., Longrois D., Lüscher T.F., Pierard L., Pocock S., Price S., Roffi M., Sirnes P.A., Sousa-Uva M., Voudris V., Funck-Brentano C. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) // Eur. Heart. J. — 2014. — Vol. 35, № 35. — Р. 2383-2431. doi: 10.1093/eurheartj/ehu282. Epub 2014 Aug 1.

Fleisher L.A., Beckman J.A., Brown K.A., Calkins H., Chaikof E.L., Fleischmann K.E., Freeman W.K., Froehlich J.B., Kasper E.K., Kersten J.R., Riegel B., Robb J.F., Smith S.C. Jr., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Buller C.E., Creager M.A., Ettinger S.M., Faxon D.P., Fuster V., Halperin J.L., Hiratzka L.F., Hunt S.A., Lytle B.W., Nishimura R., Ornato J.P., Page R.L., Riegel B., Tarkington L.G., Yancy C.W. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery // J. Am. Coll. Cardiol. — 2007. — Vol. 50, № 17. — Р. e159-е241. PMID: 17950140.

Прогнозирование и профилактика кардиальных ослож­нений внесердечных хирургических вмешательств: Национальные рекомендации / Всероссийское научное общество кардиологов. — М., 2011. —

Carroll K., Majeed A., Firth C., Gray J. Prevalence and ma­nagement of coronary heart disease in primary care: population-based cross-sectional study using a disease register // J. Public. Health. Med. — 2003. — Vol. 25, № 1. — Р. 25-29. PMID 12669915.

Добрушина О.Р., Корниенко А.Н., Шкловский Б.Л., Царев М.И. Оценка риска кардиальных осложнений при обширных абдоминальных операциях у больных пожилого и старческого возраста // Российский медицинский журнал. — 2012. — № 1. — С. 14-18.

Мороз В.В., Добрушина О.Р., Стрельникова Е.П., Корниенко А.Н., Зинина Е.П. Предикторы кардиальных ослож­нений операций на органах брюшной полости и малого таза у больных пожилого и старческого возраста // Общая реаниматология. — 2011. — Т. 7, № 5. — С. 26-31. DOI 10.15360/1813-9779-2011-5.

POISE Study Group, Devereaux P.J., Yang H., Yusuf S., Guyatt G., Leslie K., Villar J.C., Xavier D., Chrolavicius S., Greenspan L., Pogue J., Pais P., Liu L., Xu S., Málaga G., Ave­zum A., Chan M., Montori V.M., Jacka M., Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial // Lancet. — 2008. — Vol. 371, № 9627. — Р. 1839-1847. DOI 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12.

Lee T.H., Marcantonio E.R., Mangione C.M., Tho­mas E.J., Polanczyk C.A., Cook E.F., Sugarbaker D.J., Donaldson M.C., Poss R., Ho K.K., Ludwig L.E., Pedan A., Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiacsurgery // Circulation. — 1999. — Vol. 100, № 10. — Р. 1043-1049. PMID 10477528.

Abraham N., Lemech L., Sandroussi C. Sullivan D., May J. A prospective study of subclinical myocardial damage in endovascular versus open repair of infrarenal abdominal aortic aneurysms // J. Vasc. Surg. — 2005. — Vol. 41, № 3. — Р. 377-380. PMID 15838465.

Le Manach Y., Perel A., Coriat P., Godet G., Bertrand M., Riou B. Early and delayed myocardial infarction after abdominal aortic surgery // Anesthesiology. — 2005. — Vol. 102, № 5. — Р. 885-891. PMID 15851872.

Sun R.R., Lu L., Liu M., Cao Y., Li X.C., Liu H., Wang J., Zhang P.Y. Biomarkers and heart disease // Eur. Rev. Med. Pharmacol. Sci. — 2014. — Vol. 18, № 19. — Р. 2927-2935. PMID 25339488.

Вихерт А.М., Чазов Е.И. Патогенез инфаркта мио­карда // Кардиология. — 1971. — Т. 11, № 10. — С. 26-41. PMID 4944890.

Mitter N., Grogan K., Nyhan D., Berkowitz D.E. Pharmacology of Anesthetic Drugs.Kaplan’s Cardiac Anesthesia: The Echo Era / Ed.: J.A. Kaplan, D.L. Reich, J.S. Savino. — 6th edition. — Saunders, 2011. — Р. 193-234.

Opie L.H. The multifarious spectrum of ischemic left ventricular dysfunction: relevance of new ischemic syndromes // J. Mol. Cell. Cardiol. — 1996. — Vol. 28, № 12. — Р. 2403-2414. PMID 9004157.

Волкова И.И. Ремоделирование сердца и сосудов при ишемической болезни сердца // Патология кровообращения и кардиохирургия. — 2010. — № 4. — С. 96-98.

Ellis S.G., Hertzer N.R., Young J.R., Brener S. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery // Am. J. Car­diol. — 1996. — Vol. 77, № 12. — Р. 1126-1128. PMID 8644673.

Cohen M.C., Aretz T.H. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction // Cardiovasc. Pathol. — 1999. — Vol. 8, № 3. — Р. 133-139. PMID 10722235.

Dawood M.M., Gutpa D.K., Southern J., Walia A., Atkinson J.B., Eagle K.A. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention // Int. J. Cardiol. — 1996. — Vol. 57, № 1. — Р. 37-44. PMID 8960941.

Detsky A.S., Abrams H.B., McLaughlin J.R., Dru­cker D.J., Sasson Z., Johnston N., Scott J.G., Forbath N., Hilliard J.R. Predicting cardiac complications in patients undergoing non-cardiac surgery // J. Gen. Intern. Med. — 1986. — Vol. 1, № 4. — Р. 211-219. PMID 3772593.

Goldman L., Caldera D.L., Nussbaum S.R., Southwick F.S., Krogstad D., Murray B., Burke D.S., O’Malley T.A., Goroll A.H., Caplan C.H., Nolan J., Carabello B., Slater E.E. Multifactorial index of cardiac risk in noncardiac surgical procedures // N. Engl. J. Med. — 1977. — Vol. 297, № 16. — Р. 845-850. PMID 904659.

Fleisher L.A., Beckman J.A., Brown K.A., Calkins H., Chaikof E.L., Fleischmann K.E., Freeman W.K., Froehlich J.B., Kasper E.K., Kersten J.R., Riegel B., Robb J.F. 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/ AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery // Circulation. — 2009. — Vol. 120, № 22. — Р. e169-e276. doi 10.1161/CIRCULATIONAHA.109.192690. Epub 2009 Nov 2.

Mangano D.T., Layug E.L., Wallace A., Mangano D.T., Layug E.L., Wallace A., Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group // N. Engl. J. Med. — 1996. — Vol. 335, № 23. — Р. 1713-1720. PMID 8929262.

Poldermans D., Boersma E., Bax J.J., Thomson I.R., van de Ven L.L., Blankensteijn J.D., Baars H.F., Yo T.I., Trocino G., Vigna C., Roelandt J.R., van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery / Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group // N. Engl. J. Med. — 1999. — Vol. 341, № 24. — Р. 1789-1794. PMID 10588963.

Wetterslev J., Juul A.B. Benefits and harms of periope­rative beta-blockade // Best Pract. Res Clin. Anaesthesiol. — 2006. — Vol. 20, № 2. — Р. 285-302. PMID 16850778.

Beattie W.S., Wijeysundera D.N., Karkouti K. McClus­key S., Tait G., Mitsakakis N., Hare G.M. Acute surgical anemia influences the cardioprotective effects of beta-blockade: a single-center, propensity-matched cohort study // Anesthesio­logy. — 2010. — Vol. 112, № 1. — Р. 25-33. DOI 10.1097/ALN.0b013e3181c5dd81.

Feringa H.H., Vidakovic R., Karagiannis S.E., Dunkelgrun M., Elhendy A., Boersma E., van Sambeek M.R., Noordzij P.G., Bax J.J., Poldermans D. Impaired glucose regulation, elevated glycated haemoglobin and cardiacischaemic events in vascular surgery patients // Diabet Med. — 2008. — Vol. 25, № 3. — Р. 314-319. DOI 10.1111/j.1464-5491.2007.02352.x.Epub.2008 Jan. 14.

O’Neil-Callahan K., Katsimaglis G., Tepper M.R. Ryan J., Mosby C., Ioannidis J.P., Danias P.G. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study // J. Am. Coll. Cardiol. — 2005. — Vol. 45, № 3. — Р. 336-342. PMID 15680709.

Wijeysundera D.N., Beattie W.S. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis // Anesth. Analg. — 2003. — Vol. 97, № 3. — Р. 634-641. PMID 12933374.

Kertai M.D., Westerhout C.M., Varga K.S., Acsady G., Gal J. Dihydropiridine calciumchannel blockers and peri-opera­tive mortality in aortic aneurysm surgery // Br. J. Anaesthesia. — 2008. — Vol. 101, № 4. — Р. 458-465. DOI 10.1093/bja/aen173. Epub 2008 Jun 12.

Lango R., Smolenski R. T., Narkiewicz M. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass // Cardiovasc. Res. — 2001. — Vol. 51, № 1. — P. 21-29.

Асташкин Е.И., Глезер М.Г. Роль L-карнитина в энергетическом обмене кардиомиоцитов и лечении заболеваний сердечно-сосудистой системы // Кардиология и сердечно-сосудистая хирургия. — 2012. — 2. — 58-65.

Леонтьева И.В., Сухоруков В.С. Значение метаболических нарушений в генезе кардиомиопатий и возможности применения L-карнитина для терапевтической коррекции // Вестн. педиатр. фармакол. и нутрициол. — 2006. — 2. — 12-14.

Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А. и др. Первый клинический опыт применения инфузионного отечественного препарата левокарнитина при синдроме малого выброса у больных инфарктом миокарда, тромбоэмболией легочной артерии и дилатационной кардиомиопатией // Съезд ассоциации анестезиологов-реаниматологов Северо-Запада России, 6-й: Материалы // Эфферентная терапия. — 2011. — 3. — 136-137.

Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А. и др. Опыт применения инфузионного отечественного препарата левокарнитина при синдроме малого выброса у больных острым инфарктом миокарда // Бюл. НЦССХ им. А.Н. Бакулева РАМН. — 2012. — 3. — 69.

Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А., Сборщикова А.К. Положительные инотропные свойства инфузионного отечественного препарата левокарнитина у больных острым инфарктом миокарда // Международная научно-практическая конференция «Внезапная смерть: от оценки риска к профилактике», 8-я: Тезисы // Бюл. Федерального центра сердца, крови и эндокринологии им. В.А. Алмазова. — 2012. — 2 (приложение 2). — 21-22.

Arsenian M.A. Carnitine and its derivatives in cardiovascular disease // Prog. Cardiovasc. Dis. — 1997. — 40(3). — 265-286.

Bartels G.L., Remme W.J., Pillay M. et al. Effects of L-propionyl-carnitine on ischemia-induced myocardial dysfunction in men with angina pectoris // Am. J. Cardiol. — 1994. — 74(2). — 125-130.

Cacciatore L., Cerio R., Ciarimboli M. et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study // Drugs Exp. Clin. Res. — 1991. — 17(4). — 225-235.

Canale C., Terrachini V., Biagini A. et al. Bicycle ergo­meter and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracings // Int. J. Clin. Pharmacol. Ther. Toxicol. — 1988. — 26(4). — 221-224.

Cherchi A. Effects of L-carnitine on exercise tolerance in chronic-stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study // Int. J. Clin. Pharmacol. Ther. Toxicol. — 1985. — 23(10). — 569-572.

Cherchi A., Lai C, Onnis E. et al. Propionylcarnitine in stable effort angina // Cardiovasc. Drugs Ther. — 1990. — 4(2). — 581-586.

Davini P., Bigalli A., Lamanna F., Boem A. Controlled study on L-carnitine therapeutic efficacy in post infarction // Drug Exp. Clin. Res. — 1992. — 18(8). — 355-365.

Dinicolantonio J.J., Lavie C.J., Fares H., Menezes A.R., O’Keefe J.H. L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis // Mayo Clin. Proc. — 2013 Apr. — 15. — 1-8

Ferrari R., Cocchini F., Di Lisa F. et al. The effect of L-carnitine on myocardial metabolism of patients with coronary artery disease // Olin. Trials J. — 1984. — 21. — 40-58.

Ferrari R., Merli E., Cicchitelli G. et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review // Ann. N. Y. Acad. Sci. — 2004. — 1033. — 79-91.

Fujiwara M., Nakano T., Tamoto S. et al. Effect of L-carnitine in patients with ischemic heart disease // J. Car­diol. — 1991. — 21. — 493-504.

Helton E., Darragh R., Francis P. et al. Metabolic aspects of myocardial disease and a role for L-carnitine in the treatment of childhood cardiomyopathy // Pediatrics. — 2001. — 105. —1260-1270.

Iliceto S., Scrutinio D., Bruzzi P et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-сarnitine ecocardiografia digitalizzata infarto miocardico (CEDIM) Trial // JACC. — 1995. — Vol. 26, Is. 2. — 380-387.

Kamikawa T., Suzuki Y., Kobayashi A. et al. Effect of ­L-carnitine on exercise tolerance in patients with stable angina pectoris // Jpn Heart J. — 1984. — 25. — 587-597.

Kobayashi A., Masamura Y., Yamazaki N. L-Carnitine treatment for chronic heart failure — experimental and clinical study // Jpn Cire J. — 1992. — 56. — 86-94.

Lango R., Smolenski R., Narkiewicz M. et al. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass // Cardiovasc. Res. — 2001. — 51. — 21-29.

Opie L.H. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium // Am. Heart J. — 1979. — 97. — 375-388.

Rahbar A., Shakerhosseini R., Saadat N. et al. Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus // Eur. J. Clin. Nutr. — 2005. — 59 (4). — 592-596.

Rebouche C.J., Engel A.G. Carnitine metabolism and deficiency syndromes // Mayo Clin. Proc. — 1983. — 58. — 533-540.

Rebuzzi A.G., Schiavoni G., Amico C.M. et al. Beneficial effect of L-carnitine in the reduction of necrotic area in acute myocardial infarction // Drugs Exp. Clin. Res. — 1984. — 10. — 219-223.

Regitz V., Shug A.L., Fleck E. Defective myocardial metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart di­seases // Am. J. Cardiol. — 1990. — 65. — 755-760.

Rizzon P., Biaseo G., Boscia F. et al. High doses of ­L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects // Eur. Hear J. — 1989. — 10. — 502-508.

Shag A.L., Thomsen J.H., Folts J.D. et al. Changes in tissue levels of carnitine and other metabolites during isehaemia and anoxia // Arch. Biochem. Biophys. — 1978. — 187. — 25.

Singh R.B., Niaz M.A., Agarwal P. et al. A randomized, doubleblind, placebo controlled trial of L-carnitine in suspected myocardial infarction // Postgrad. Med. J. — 1996. — 72, 843. — 45-50.

Spagnoli L.G., Corsi M., Villaschi S. et al. Myocardial carnitine deficiency in acute myocardial infarction // Lancet. — 1982. — 1. — 1419-1420.

Suzuki Y., Masumura Y., Kobayashi A. et al. Myocardial carnitine deficiency in chronic heart failure // Lancet. — 1982. — 1. — 116.

Suzuki Y., Kawikawa T., Kobayashi A. et al. Effects of L-carnitine on tissue levels of acyl carnitine, acyl coenzyme A and high energy phosphate in ischemic dog hearts // Jpn Circ. J. — 1981. — 45. — 687-694.

Tarantini G., Scrutinio D., Bruzzi P et al. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial // Cardio­logy. — 2006. — Vol. 106, № 4. — 215-223.

Thomsen J.H., Shug A.L. Yap V.U. et al. Improved pacing tolerance of the ischemic human myocardium after administration of carnitine // Am. J. Cardiol. — 1979. — 43. — 300-306.

Copyright (c) 2017 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта